{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:34:10Z","timestamp":1788885250188,"version":"build-2803163510"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s41669-025-00619-6","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:18:21Z","timestamp":1763270301000},"page":"121-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-4578","authenticated-orcid":false,"given":"Iago","family":"Rodr\u00edguez-Lago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-7240","authenticated-orcid":false,"given":"Fernando","family":"Mu\u00f1oz N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1072","authenticated-orcid":false,"given":"Alfredo J.","family":"Lucendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"De Lossada Juste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cabez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-3049","authenticated-orcid":false,"given":"Alberto","family":"de la Cuadra-Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-6152","authenticated-orcid":false,"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-2601","authenticated-orcid":false,"given":"Emilio","family":"Monte-Boquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"619_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403:1177\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(23)02586-2.","journal-title":"Lancet"},{"key":"619_CR2","unstructured":"Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU), Hinojosa del Val JE, Nos Mateu P. Manual pr\u00e1ctico: Conductas de actuaci\u00f3n en la enfermedad inflamatoria cr\u00f3nica intestinal. 8a. Madrid: GETECCU;"},{"key":"619_CR3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","volume":"330","author":"B Gros","year":"2023","unstructured":"Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330:951\u201365. https:\/\/doi.org\/10.1001\/jama.2023.15389.","journal-title":"JAMA"},{"key":"619_CR4","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","journal-title":"Lancet"},{"key":"619_CR5","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","volume":"40","author":"M Barreiro-de Acosta","year":"2023","unstructured":"Barreiro-de Acosta M, Molero A, Artime E, D\u00edaz-Cerezo S, Liz\u00e1n L, de Paz HD, et al. Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn\u2019s disease) in Spain: a systematic review. Adv Ther. 2023;40:1975\u20132014. https:\/\/doi.org\/10.1007\/s12325-023-02473-6.","journal-title":"Adv Ther"},{"key":"619_CR6","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/jcm10132885","volume":"10","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, N\u00fa\u00f1ez Ortiz A, Diz-Lois Palomares MT, Rodr\u00edguez C, Riestra S, et al. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. J Clin Med. 2021;10:2885. https:\/\/doi.org\/10.3390\/jcm10132885.","journal-title":"J Clin Med"},{"key":"619_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642:458\u201366. https:\/\/doi.org\/10.1038\/s41586-025-08940-0.","journal-title":"Nature"},{"key":"619_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ecco-jcc\/jjy024","volume":"12","author":"A Yarlas","year":"2018","unstructured":"Yarlas A, Rubin DT, Pan\u00e9s J, Lindsay JO, Vermeire S, Bayliss M, et al. Burden of ulcerative colitis on functioning and well-being: a systematic literature review of the SF-36\u00ae health survey. J Crohns Colitis. 2018;12:600\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy024.","journal-title":"J Crohns Colitis"},{"key":"619_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","volume":"5","author":"J Burisch","year":"2020","unstructured":"Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kup\u010dinskas J, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5:454\u201364. https:\/\/doi.org\/10.1016\/S2468-1253(20)30012-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"619_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastrohep.2015.04.007","volume":"39","author":"X Aldeguer","year":"2016","unstructured":"Aldeguer X, Sicras-Mainar A. Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: a database study. Gastroenterol Hepatol. 2016;39:9\u201319. https:\/\/doi.org\/10.1016\/j.gastrohep.2015.04.007.","journal-title":"Gastroenterol Hepatol"},{"key":"619_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322\u201337. https:\/\/doi.org\/10.1016\/j.crohns.2013.01.010.","journal-title":"J Crohns Colitis"},{"key":"619_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/ibd\/izac144","volume":"29","author":"P Holko","year":"2022","unstructured":"Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M. Indirect costs of inflammatory bowel diseases: a comparison of patient-reported outcomes across 12 European countries. Inflamm Bowel Dis. 2022;29:752\u201362. https:\/\/doi.org\/10.1093\/ibd\/izac144.","journal-title":"Inflamm Bowel Dis"},{"key":"619_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/pharmaceutics16050629","volume":"16","author":"C G\u00f3mez-Labrador","year":"2024","unstructured":"G\u00f3mez-Labrador C, Ricart E, Iborra M, Iglesias E, Mart\u00edn-Arranz MD, De Castro L, et al. Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA. Pharmaceutics. 2024;16:629. https:\/\/doi.org\/10.3390\/pharmaceutics16050629.","journal-title":"Pharmaceutics"},{"key":"619_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11938-020-00299-7","volume":"18","author":"R Sedano","year":"2020","unstructured":"Sedano R, Almradi A, Ma C, Jairath V, Feagan BG. Novel therapeutics for the treatment of IBD: current status and future directions. Curr Treat Options Gastroenterol. 2020;18:442\u201361. https:\/\/doi.org\/10.1007\/s11938-020-00299-7.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"619_CR15","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Velsipity. Madrid: AEMPS; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/velsipity-epar-product-information_en.pdf. Accessed 17 Jan 2025"},{"key":"619_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(23)00061-2.","journal-title":"Lancet"},{"key":"619_CR17","unstructured":"European Medicines Agency (EMA). Velsipity. Amsterdam: EMA; 2024 Feb. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/velsipity. Accessed 5 Feb 2025"},{"key":"619_CR18","unstructured":"Center for Drug Evaluation and Research. Novel drug approvals for 2023. New Hampshire: Food and Drug Administration (FDA); 2025. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2023. Accessed 7 Feb 2025"},{"key":"619_CR19","doi-asserted-by":"crossref","unstructured":"Canada\u2019s Drug Agency \u2013 L\u2019Agence des M\u00e9dicaments du Canada (CDA-AMC). Reimbursement Review - Etrasimod (Velsipity). Canadian Journal of Health Technologies. 2024;4. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2024\/SR0795_Velsipity_Combined_Review.pdf. Accessed 6 Feb 2025","DOI":"10.51731\/cjht.2024.1037"},{"key":"619_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. London: NICE; 2024. https:\/\/www.nice.org.uk\/guidance\/ta956\/resources\/etrasimod-for-treating-moderately-to-severely-active-ulcerative-colitis-in-people-aged-16-and-over-pdf-82615732361413. Accessed 7 Feb 2025"},{"key":"619_CR21","volume-title":"Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos","author":"EA Ortega","year":"2017","unstructured":"Ortega EA. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos. Madrid: SEFH, Sociedad Espa\u00f1ola de Farmacia Hospitalaria; 2017."},{"key":"619_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Londres: NICE; 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 2 Jan 2023"},{"key":"619_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2025.102448","volume":"39","author":"M Trapero-Bertran","year":"2025","unstructured":"Trapero-Bertran M, Oliva J, Catal\u00e1-L\u00f3pez F, Garc\u00eda-P\u00e9rez L, Seg\u00fa L, Alegre-del-Rey EJ, et al. Guideline for the economic evaluation of medicines: a proposal by the Spanish National Health System\u2019s Advisory Committee for Pharmaceutical Financing. Gac Sanit. 2025;39:102448. https:\/\/doi.org\/10.1016\/j.gaceta.2025.102448.","journal-title":"Gac Sanit"},{"key":"619_CR24","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Humira. Madrid: AEMPS; 2008. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/103256021\/FT_103256021.html"},{"key":"619_CR25","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Yuflyma. Madrid: AEMPS; 2021. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/p\/1201513015\/1201513015_p.pdf"},{"key":"619_CR26","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Hulio. Madrid: AEMPS; 2018. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181319005\/FT_1181319005.html"},{"key":"619_CR27","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Imraldi. Madrid: AEMPS; 2022. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1171216010\/FT_1171216010.html"},{"key":"619_CR28","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Hyrimoz. Madrid: AEMPS; 2018. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181286004\/FT_1181286004.html"},{"key":"619_CR29","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Amgevita. Madrid: AEMPS; 2017. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1161164002\/FT_1161164002.html"},{"key":"619_CR30","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Simponi. Madrid: AEMPS; 2014. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/109546005\/FT_109546005.html"},{"key":"619_CR31","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Dicha T\u00e9cnica de Remicade. Madrid: AEMPS; 1999. https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/99116001\/FT_99116001.pdf"},{"key":"619_CR32","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Inflectra. Madrid: AEMPS; 2018. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/113854001\/FT_113854001.html"},{"key":"619_CR33","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Remsima. Madrid: AEMPS; 2019. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1130853006\/FT_1130853006.html"},{"key":"619_CR34","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Zessly. Madrid: AEMPS; 2022. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181280001\/FT_1181280001.html"},{"key":"619_CR35","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Flixabi. Madrid: AEMPS; 2022. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1161106001\/FT_1161106001.html"},{"key":"619_CR36","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Stelara. Madrid: AEMPS; 2021. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/08494003\/FT_08494003.html"},{"key":"619_CR37","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Entyvio en polvo para concentrado para perfusi\u00f3n. Madrid: AEMPS; 2018. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/114923001\/FT_114923001.html"},{"key":"619_CR38","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Entyvio en soluci\u00f3n inyectable en jeringa precargada. Madrid: AEMPS; 2020. https:\/\/cima.aemps.es\/cima\/dochtml\/p\/114923002\/P_114923002.html"},{"key":"619_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25:10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008.","journal-title":"Value Health"},{"key":"619_CR40","unstructured":"Jairath V, Leahy TP, Potluri R, Wosik K, Gruben D, Cappelleri JC, et al. Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis na\u00efve to advanced therapy. Sweden: 19th Congress of European Crohn\u2019s and Colitis Organisation (ECCO); 2024. https:\/\/scientificpubs.congressposter.com\/p\/k0b1nw0im7astcj2. Accessed 5 Feb 2025"},{"key":"619_CR41","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0225","volume":"14","author":"V Jairath","year":"2025","unstructured":"Jairath V, Raine T, Leahy TP, Potluri R, Wosik K, Gruben D, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis. J Comp Eff Res. 2025;14:e240225. https:\/\/doi.org\/10.57264\/cer-2024-0225.","journal-title":"J Comp Eff Res"},{"key":"619_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091961","volume":"15","author":"JD Guo","year":"2025","unstructured":"Guo JD, Gehchan A, Hartzema A. Selection of indirect treatment comparisons for health technology assessments: a practical guide for health economics and outcomes research scientists and clinicians. BMJ Open. 2025;15:e091961. https:\/\/doi.org\/10.1136\/bmjopen-2024-091961.","journal-title":"BMJ Open"},{"key":"619_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10620-019-05867-1","volume":"65","author":"YS Jung","year":"2020","unstructured":"Jung YS, Han M, Park S, Cheon JH. Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: a nationwide population-based study. Dig Dis Sci. 2020;65:1436\u201344. https:\/\/doi.org\/10.1007\/s10620-019-05867-1.","journal-title":"Dig Dis Sci"},{"key":"619_CR44","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/00365521.2023.2173988","volume":"58","author":"KJ Jensen","year":"2023","unstructured":"Jensen KJ, Jensen CB, Wennerstr\u00f6m C, Burisch J, Petersen J. Drug utilization of biologic therapy in Crohn\u2019s disease and ulcerative colitis: a population-based Danish cohort study 2015\u20132020. Scand J Gastroenterol. 2023;58:726\u201336. https:\/\/doi.org\/10.1080\/00365521.2023.2173988.","journal-title":"Scand J Gastroenterol"},{"key":"619_CR45","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/ibd\/izad245","volume":"30","author":"N Krugliak Cleveland","year":"2023","unstructured":"Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, et al. Real-world persistence of successive biologics in patients with inflammatory bowel disease: findings from ROTARY. Inflamm Bowel Dis. 2023;30:1776\u201387. https:\/\/doi.org\/10.1093\/ibd\/izad245.","journal-title":"Inflamm Bowel Dis"},{"key":"619_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041357","volume":"14","author":"P Markopoulos","year":"2025","unstructured":"Markopoulos P, Gaki A, Kokkotis G, Chalakatevaki K, Kioulos N, Kitsou V, et al. Temporal trends in the use of biological agents in patients with inflammatory bowel disease: real-world data from a tertiary inflammatory bowel disease Greek center during a 5-year period. J Clin Med. 2025;14:1357. https:\/\/doi.org\/10.3390\/jcm14041357.","journal-title":"J Clin Med"},{"key":"619_CR47","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Engl J Med"},{"key":"619_CR48","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/apt.13291","volume":"42","author":"P Rutgeerts","year":"2015","unstructured":"Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42:504\u201314. https:\/\/doi.org\/10.1111\/apt.13291.","journal-title":"Aliment Pharmacol Ther"},{"key":"619_CR49","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Jyseleca. Madrid: AEMPS; 2020. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1201480003\/FT_1201480003.html"},{"key":"619_CR50","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Xeljanz. Madrid: AEMPS; 2022. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1171178003\/FT_1171178003.html"},{"key":"619_CR51","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Rinvoq. Madrid: AEMPS; 2019. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1191404001\/FT_1191404001.html"},{"key":"619_CR52","unstructured":"National Institute for Health and Care Excellence (NICE). Ustekinumab for moderately to severely active ulcerative colitis (TA633). Londres: NICE; 2020. https:\/\/www.nice.org.uk\/guidance\/ta633. Accessed 4 Sep 2023"},{"key":"619_CR53","unstructured":"National Institute for Health and Care Excellence (NICE). Upadacitinib for moderately to severely active ulcerative colitis (TA856). Londres: NICE; 2023. https:\/\/www.nice.org.uk\/guidance\/ta856. Accessed 4 Sept 2023"},{"key":"619_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.dld.2020.09.026","volume":"53","author":"M Guasch","year":"2021","unstructured":"Guasch M, Vela E, Ma\u00f1osa M, Cl\u00e8ries M, Ca\u00f1ete F, Par\u00e9s D, et al. Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: a population-based study in Southern Europe. Dig Liver Dis. 2021;53:54\u201360. https:\/\/doi.org\/10.1016\/j.dld.2020.09.026.","journal-title":"Dig Liver Dis"},{"key":"619_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.gastrohep.2022.08.010","volume":"46","author":"L N\u00fa\u00f1ez","year":"2023","unstructured":"N\u00fa\u00f1ez L, Mesonero F, Rodr\u00edguez de Santiago E, Die J, Albillos A, L\u00f3pez-Sanrom\u00e1n A. High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified. Gastroenterol Hepatol. 2023;46:369\u201375. https:\/\/doi.org\/10.1016\/j.gastrohep.2022.08.010.","journal-title":"Gastroenterol Hepatol"},{"key":"619_CR56","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.3390\/jcm10194402","volume":"10","author":"MJ Garc\u00eda","year":"2021","unstructured":"Garc\u00eda MJ, Rivero M, Miranda-Bautista J, Bast\u00f3n-Rey I, Mesonero F, Leo-Carnerero E, et al. Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of Geteccu. J Clin Med. 2021;10:4402. https:\/\/doi.org\/10.3390\/jcm10194402.","journal-title":"J Clin Med"},{"key":"619_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/ibd.20278","volume":"14","author":"M Ferrante","year":"2008","unstructured":"Ferrante M, Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20\u20138. https:\/\/doi.org\/10.1002\/ibd.20278.","journal-title":"Inflamm Bowel Dis"},{"key":"619_CR58","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Demograf\u00eda y poblaci\u00f3n: Fen\u00f3menos demogr\u00e1ficos - Tablas de mortalidad. Madrid: INE; https:\/\/ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736177004&menu=ultiDatos&idp=1254735573002. Accessed 19 June 2024"},{"key":"619_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1572-0241.2006.01000.x","volume":"102","author":"T Jess","year":"2007","unstructured":"Jess T, Gamborg M, Munkholm P, S\u00f8rensen TIA. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol. 2007;102:609\u201317. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.01000.x.","journal-title":"Am J Gastroenterol"},{"key":"619_CR60","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF). BOTPlus. Madrid: CGCOF; 2023. https:\/\/botplusweb.farmaceuticos.com\/. Accessed 21 Aug 2023"},{"key":"619_CR61","unstructured":"Jefatura del Estado. Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. S ect. 1, Real Decreto-ley 8\/2010 May 24, 2010 p. 45070\u2013128. https:\/\/www.boe.es\/eli\/es\/rdl\/2010\/05\/20\/8. Accessed 23 May 2024"},{"key":"619_CR62","unstructured":"Ministerio de Sanidad. Portal Estad\u00edstico: \u00c1rea de Inteligencia de Gesti\u00f3n. Madrid: Ministerio de Sanidad; 2023. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/N\/rae-cmbd\/rae-cmbd\/grupos-relacionados-por-el-diagnostico-grd. Accessed 8 Nov 2023"},{"key":"619_CR63","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Immufalk. Madrid: AEMPS; 2024. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/78164\/FT_78164.html.pdf. Accessed 20 Jan 2025"},{"key":"619_CR64","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Mercaptopurina Aspen. Madrid: AEMPS; 2022. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/34565\/FT_34565.html"},{"key":"619_CR65","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Metotrexato semanal Cipla. Madrid: AEMPS; 2023. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/79758\/FichaTecnica_79758.html"},{"key":"619_CR66","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Asacol. Madrid: AEMPS; 2008. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/57726\/FT_57726.html. Accessed 5 Sept 2023"},{"key":"619_CR67","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Prednisona Cinfa EFG. Madrid: AEMPS; 2020. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/75649\/FT_75649.html. Accessed 5 Sept 2023"},{"key":"619_CR68","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica de Clipper. Madrid: AEMPS; 2019. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/66706\/FT_66706.html.pdf. Accessed 20 Jan 2025"},{"key":"619_CR69","unstructured":"National Institute for Health and Care Excellence (NICE). Ozanimod for moderately to severely active ulcerative colitis (TA828). Londres: NICE; 2022. https:\/\/www.nice.org.uk\/guidance\/ta828. Accessed 4 Sep 2023"},{"key":"619_CR70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/14737167.2018.1411193","volume":"18","author":"C Trigo-Vicente","year":"2018","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, Montoiro-Allu\u00e9 R, L\u00f3pez-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2018;18:321\u20139. https:\/\/doi.org\/10.1080\/14737167.2018.1411193.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"619_CR71","unstructured":"Instituto Nacional de Estad\u00edstica (INE). \u00cdndice de precios de consumo. Madrid: INE; https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176802&menu=ultiDatos&idp=1254735976607. Accessed 5 Dec 2024"},{"key":"619_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.2224","volume":"18","author":"C Kosmas","year":"2015","unstructured":"Kosmas C, Kerr C, Marsh S, Gentile B, Doll H, Finney-Hayward T. Health related quality of life (Hrqol) in patients who have undergone colectomy for ulcerative colitis: impacts of complications post-surgery. Value Health. 2015;18:A630. https:\/\/doi.org\/10.1016\/j.jval.2015.09.2224.","journal-title":"Value Health"},{"key":"619_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"M Stevenson","year":"2016","unstructured":"Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20:1\u2013610. https:\/\/doi.org\/10.3310\/hta20350.","journal-title":"Health Technol Assess"},{"key":"619_CR74","unstructured":"Comit\u00e9 Asesor para la Financiaci\u00f3n de la prestaci\u00f3n Farmac\u00e9utica del SNS. Gu\u00eda de Evaluaci\u00f3n Econ\u00f3mica de Medicamentos. Madrid: Ministerio de Sanidad; 2024. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20240227_CAPF_Guia_EE_definitiva.pdf. Accessed 13 Sep 2024"},{"key":"619_CR75","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Rivero-Arias O, Pinto-Prades J, Serrano-Aguilar P. Disposici\u00f3n a pagar de la sociedad espa\u00f1ola por un A\u00f1o de Vida Ajustado por Calidad. Canarias: Servicio de Evaluaci\u00f3n del Servicio Canario de Salud (SESCS); 2016. https:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/content\/c6b59111-420f-11e7-952b-a987475f03d3\/SESCS_2016_DAP_AVAC.pdf. Accessed 28 Sep 2023"},{"key":"619_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gaceta.2019.06.007","volume":"34","author":"JA Sacrist\u00e1n","year":"2020","unstructured":"Sacrist\u00e1n JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, et al. Qu\u00e9 es una intervenci\u00f3n sanitaria eficiente en Espa\u00f1a en 2020? Gac Sanit. 2020;34:189\u201393. https:\/\/doi.org\/10.1016\/j.gaceta.2019.06.007.","journal-title":"Gac Sanit"},{"key":"619_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01441-4","author":"L Vallejo-Torres","year":"2024","unstructured":"Vallejo-Torres L. Estimating the incremental cost per QALY produced by the Spanish NHS: a fixed-effect econometric approach. Pharmacoeconomics. 2024. https:\/\/doi.org\/10.1007\/s40273-024-01441-4.","journal-title":"Pharmacoeconomics"},{"key":"619_CR78","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/MEG.0000000000002751","volume":"36","author":"T Rokkas","year":"2024","unstructured":"Rokkas T, Gisbert JP, Ekmektzoglou K, Dassopoulos T, Niv Y, O\u2019Morain C. Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis. Eur J Gastroenterol Hepatol. 2024;36:520\u201333. https:\/\/doi.org\/10.1097\/MEG.0000000000002751.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"619_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae308","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Allegretti JR, Loftus EV, Irving PM, Banerjee R, Charabaty A, et al. Assessment and impact of age on the safety and efficacy of etrasimod in patients with ulcerative colitis: a post hoc analysis of data from the ELEVATE UC clinical program. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izae308.","journal-title":"Inflamm Bowel Dis"},{"key":"619_CR80","unstructured":"Woehl A, Hawthorne A, McEwan P. The relation between disease activity, quality of life and health utility in patients with ulcerative colitis. Gut. 2008."},{"key":"619_CR81","doi-asserted-by":"publisher","first-page":"A237.2","DOI":"10.1136\/gutjnl-2012-302514c.127","volume":"61","author":"P Swinburn","year":"2012","unstructured":"Swinburn P, Elwick H, Bean K, Curry A, Patel S, Bodger K, et al. PTU-127 The impact of surgery on health related quality of life in ulcerative colitis: abstract PTU-127 figure 1. Gut. 2012;61:A237.2-A237. https:\/\/doi.org\/10.1136\/gutjnl-2012-302514c.127.","journal-title":"Gut"},{"key":"619_CR82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/flgastro-2013-100409","volume":"5","author":"CJ Vaizey","year":"2014","unstructured":"Vaizey CJ, Gibson PR, Black CM, Nicholls RJ, Weston AR, Gaya DR, et al. Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterol. 2014;5:183\u20139. https:\/\/doi.org\/10.1136\/flgastro-2013-100409.","journal-title":"Frontline Gastroenterol"},{"key":"619_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2025.502363","volume":"48","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Chaparro M. Etrasimod: review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis. Gastroenterol Hepatol. 2025;48:502363. https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502363.","journal-title":"Gastroenterol Hepatol"},{"key":"619_CR84","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.18133","volume":"60","author":"R Ferreiro-Iglesias","year":"2024","unstructured":"Ferreiro-Iglesias R, Porto Silva S, Mar\u00edn S, Casanova MJ, Ma\u00f1osa M, Gonz\u00e1lez-Mu\u00f1oza C, et al. Need for therapeutic escalation in patients with refractory ulcerative proctitis: results from the PROCU study of the ENEIDA registry. Aliment Pharmacol Ther. 2024;60:604\u201312. https:\/\/doi.org\/10.1111\/apt.18133.","journal-title":"Aliment Pharmacol Ther"},{"key":"619_CR85","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","volume":"18","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Dubinsky MC, Sands BE, Pan\u00e9s J, Schreiber S, Reinisch W, et al. Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme. J Crohns Colitis. 2024;18:1270\u201382. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae038.","journal-title":"J Crohns Colitis"},{"key":"619_CR86","doi-asserted-by":"publisher","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, Val AL-D. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm. British Medical Journal Publishing Group; 2020;27:355\u201360. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001833","DOI":"10.1136\/ejhpharm-2018-001833"},{"key":"619_CR87","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/14737167.2021.1880324","volume":"22","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, De Andr\u00e9s-Nogales F, Garc\u00eda-L\u00f3pez S, S\u00e1nchez-Guerrero A, Mench\u00e9n B, Peral C, et al. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022;22:73\u201383. https:\/\/doi.org\/10.1080\/14737167.2021.1880324.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"619_CR88","unstructured":"Member State Coordination Group on Health Technology Assessment. Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. Bruselas: Comisi\u00f3n Europea; 2024. https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf&prefLang=el. Accessed 10 Sep 2024"},{"key":"619_CR89","unstructured":"Member State Coordination Group on Health Technology Assessment. Practical guideline for quantitative evidence synthesis: direct and indirect comparisons. Bruselas: Comisi\u00f3n Europea; 2024. https:\/\/health.ec.europa.eu\/document\/download\/1f6b8a70-5ce0-404e-9066-120dc9a8df75_en?filename=hta_practical-guideline_direct-and-indirect-comparisons_en.pdf. Accessed 10 Sep 2024"},{"key":"619_CR90","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","volume":"40","author":"JE Brady","year":"2018","unstructured":"Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40:1509-1521.e5. https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.013.","journal-title":"Clin Ther"},{"key":"619_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.07.044","author":"A Buisson","year":"2025","unstructured":"Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, et al. Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.07.044.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"619_CR92","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i29.107745","volume":"31","author":"M Imbrizi","year":"2025","unstructured":"Imbrizi M, Azevedo MFC, Baima JP, Queiroz NSF, Parra RS, Ferreira SDC, et al. Positioning and sequencing of advanced therapies in inflammatory bowel disease: a guide for clinical practice. World J Gastroenterol. 2025;31:107745. https:\/\/doi.org\/10.3748\/wjg.v31.i29.107745.","journal-title":"World J Gastroenterol"},{"key":"619_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf161","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Chaparro M. Combination therapy with biologics and\/or small molecules in inflammatory bowel disease: a comprehensive review. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf161.","journal-title":"J Crohns Colitis"},{"key":"619_CR94","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ibd\/izae162","volume":"31","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Schreiber S, Siegel CA, Magro F, Jus A, Whichello C, et al. Benefit-risk trade-offs and patient preferences for therapy selection in ulcerative colitis: a multicountry preference study. Inflamm Bowel Dis. 2025;31:1281\u201394. https:\/\/doi.org\/10.1093\/ibd\/izae162.","journal-title":"Inflamm Bowel Dis"},{"key":"619_CR95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1478-7547-7-20","volume":"7","author":"F Xie","year":"2009","unstructured":"Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc. 2009;7:20. https:\/\/doi.org\/10.1186\/1478-7547-7-20.","journal-title":"Cost Eff Resour Alloc"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00619-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00619-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00619-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:26:37Z","timestamp":1768472797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00619-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00619-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ALJ and AC participated in the project conceptualization and definition of model inputs. ADC and IO participated in the conceptualization, definition of model inputs, model adaptation, data analyses and first draft of the manuscript. IRL, FMN, AJL and EMB validated the model structure and the inputs and provided information about management of patients with ulcerative colitis in Spain. All the authors contributed to interpretation of the results, reviewed, edited and approved the final version of the manuscript and consented to its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributors"}},{"value":"IRL, FMN, AJL and EMB have received fees for their scientific advice and contribution to the publication. IRL is supported by a research grant from Gobierno Vasco-Eusko Jaurlaritza [Grant No 2020111061 and 2023222006]; has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Alfasigma, Biogen, Chiesi, Faes Farma, Ferring, Fresenius Kabi, Galapagos, Johnson & Johnson, Eli Lilly, Mirum Pharmaceuticals, Merck, Pfizer, Roche, Takeda, and Tillotts Pharma; and receives research funding from Abbvie. FMN has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Alfasigma, Faes Farma, Ferring, Galapagos, Johnson & Johnson, Eli Lilly, Pfizer, Takeda, and Tillotts Pharma. AC and ALJ are employees of Pfizer SLU. ACG and IO are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consultant company specializing in health economics and outcomes research, which has received fees from Pfizer SLU for conducting the present analysis. EMB has received grants\/research supports or participated in educational activities, research projects, scientific meetings (either attendance, speaking and\/or delivering presentations) and advisory boards sponsored by Abbott\/Abbvie, Amgen, Astellas, Astra Zeneca, Baxalta, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chiesi, CSL Behring, Eisai, Fresenius, Galapagos, Gilead, GSK, Ipsen, Janssen, Leo Pharma, Lilly, MSD, Merck-Serono, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Theramex, UCB and ViiV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All the data used to conduct the present study are publicly available and\/or presented in the manuscript or its supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The economic model used to develop this project is owned by Pfizer and is not publicly available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable to the present study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and Public Involvement"}},{"value":"Not applicable to the present study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent for Publication"}},{"value":"Not applicable to the present study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}